A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0328 in Healthy Young Japanese and Caucasian Male Volunteers After Oral Single and Multiple Ascending Doses.

Trial Profile

A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0328 in Healthy Young Japanese and Caucasian Male Volunteers After Oral Single and Multiple Ascending Doses.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2010

At a glance

  • Drugs AZD 0328 (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Schizophrenia
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Sep 2008 Planned end date changed from 1 Sep 2008 to 1 Oct 2008 as reported by ClinicalTrials.gov.
    • 29 Sep 2008 Planned number of patients changed from 48 to 64 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top